br Acknowledgement br Special thanks to Dr
Special thanks to Dr. Austin Cape for his helpful editing advances.
The authors declare that they have no competing interests.
Ling Su and Xiangguo Liu conceived the project. Shun Yao, Xiangguo Liu, and Ling Su designed experiments and analyzed data and drafted the manuscript. Shun Yao, Feifei Shi and Wenbo Sun and Yifeng Zhang conducted the experiments. Xiaoyang Sun, Yingying Wang and Xianfang Liu contributed to animal experiments. All authors have read and approved the final manuscript.
 M.E. Beckner, H.C. Krutzsch, M.L. Stracke, S.T. Williams, J.A. Gallardo, L.A. Liotta, Identifi-cation of a new immunoglobulin superfamily protein expressed in blood vessels with a heparinbinding consensus sequence, Cancer Res. 55 (1995)
 P. Holvoet, P. Sinnaeve, Angio-associated migratory cell protein and smooth muscle cell migration in development of restenosis and atherosclerosis, J. Am. College Cardiol 52 (4) (2008) 312–314.
N. Goldberger, et al., Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile, Cancer Res. 61 (2001)
 A. Tartarone, R. Lerose, Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance, Ther. Adv. Resp. Dis 9 (2015) 242–250.
 J. Remon, T. Moran, M. Majem, N. Reguart, E. Dalmau, D. Marquez-Medina, et al., Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins, Cancer Treat. Rev. 40 (2014) 93–101.
 J. Tong, P. Taylor, M.F. Moran, Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor ATPγS tetralithium salt in response to EGF and stress, Mol. Cell. Proteomics 13 (7)
 T. Mitsudomi, S. Morita, Y. Yatabe, et al., West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer har-bouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol 11 (2) (2010) 121–128.
 Myung-Ju Ahn, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, EGFR TKI combination with immunotherapy in non-small cell lung cancer, Expert Opin. Drug Cellular Signalling 61 (2019) 10–19
 K.L. Reckamp, P.H. Frankel, N. Ruel, P.C. Mack, B.J. Gitlitz, T. Li, et al., Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy: a California Cancer Consortium phase II trial (NCI 9303), Front. Oncol. 9 (2019) 132.  Z.Y. He, M.F. Li, J.H. Lin, D. Lin, R.J. Lin, Comparing the eﬃcacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study, Cancer Manag. Res. 11 (2019) 2129–2138.
Contents lists available at ScienceDirect
Pathology - Research and Practice
journal homepage: www.elsevier.com/locate/prp
ANGPTL6-mediated angiogenesis promotes alpha fetoprotein-producing gastric cancer progression
Erbao Chena,1, Cheng Tanga,1, Ke Penga, Xi Chenga, Yichou Weia, Tianshu Liua,b,
a Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
b Center of Evidence-based Medicine, Fudan University, Shanghai, China
Alpha-fetoprotein producing-gastric cancer
Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC) is regarded as a rare but highly malignant gastric adenocarcinoma subtype and its clinic pathological presentation mimics hepatocellular carcinoma. However, the underlying mechanism of this disease remains elusive. The level of ANGPTL6 in AFPGC cell lines is much higher than that of common types of gastric cancer cells. A high level of ANGPTL6 confers a poor prognosis and is correlated with the expression of CD34 (an endothelial cell marker). ANGPTL6 promotes endothelial cell mi-gration and tube formation, Moreover, ANGPTL6 knockdown inhibits cancer cell apoptosis and invasiveness. Mechanistically, ANGPTL6 activates the ERK1/2 and AKT pathways. Treatment of ERK1/2 or AKT inhibitor can attenuated cell migration and tube formation. ANGPTL6 loss results in tumor growth in vivo. Our study revealed that ANGPTL6 is an important driver gene of angiogenesis in AFPGC development. These findings provide not only an eﬀective biomarker for diagnosis but also an attractive therapeutic target for use in AFPGC patients.